Sarah has over 20 years’ experience drafting, prosecuting and defending patents, primarily before the European Patent Office (EPO). She practices across a broad biotechnology subject matter base, including sequencing technology, genetics, gene delivery, vaccines, antibodies, diagnostic markers, personalised medicine, pharmaceutical formulation and dosage regimens and research tools, and mutant enzymes for Cleantech applications.
Sarah has an extensive opposition practice, both defending and attacking, before the Opposition Division and Boards of Appeal at the EPO, notably on early cases relating to research tools such as PCR and more recently in relation to antibody therapeutics. She has also provided litigation support, particularly on cases where she has been handling related oppositions at the EPO.
A substantial amount of Sarah’s work is for US companies and universities, both direct and through US attorney firms, prosecuting applications at the EPO and defending the resulting granted European patents in oppositions.
Her client base also includes UK universities and companies, and a number of Swedish companies. She has provided advice to many small and medium-sized companies, including filing strategies and portfolio reviews, drafting specifications, and coordinating and managing foreign filings.
Sarah joined J A Kemp in 1997, after working elsewhere in private practice since 1990, and became a partner at J A Kemp in 2002. She is also a member of the firm's management committee.
University of Cambridge, Masters Degree in Natural Sciences (Cellular and Genetic Pathology and Virology)
European Patent Attorney, UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA), Member of the Institute of Professional Representatives before the European Patent Office (EPI), Member of the UK BioIndustry Association (BIA) Intellectual Property Advisory Committee.